Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.

Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, Swenson DL, Bavari S, Kobinger GP, Geisbert TW, Aman MJ.

J Infect Dis. 2018 Nov 22;218(suppl_5):S553-S564. doi: 10.1093/infdis/jiy316.

2.

AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.

Heald AE, Charleston JS, Iversen PL, Warren TK, Saoud JB, Al-Ibrahim M, Wells J, Warfield KL, Swenson DL, Welch LS, Sazani P, Wong M, Berry D, Kaye EM, Bavari S.

N Engl J Med. 2015 Jul 23;373(4):339-48. doi: 10.1056/NEJMoa1410345.

3.

Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW, Shulenin S, Vu H, Swenson DL, Bavari S, Aman MJ.

PLoS One. 2015 Mar 20;10(3):e0118881. doi: 10.1371/journal.pone.0118881. eCollection 2015.

4.

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S.

Nat Med. 2010 Sep;16(9):991-4. doi: 10.1038/nm.2202. Epub 2010 Aug 22.

PMID:
20729866
5.

Using mortality risk scores for long-term prognosis of nursing home residents: caution is recommended.

Kruse RL, Parker Oliver D, Mehr DR, Petroski GF, Swenson DL, Zweig SC.

J Gerontol A Biol Sci Med Sci. 2010 Nov;65(11):1235-41. doi: 10.1093/gerona/glq120. Epub 2010 Jul 17.

PMID:
20639529
6.

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.

Antimicrob Agents Chemother. 2009 May;53(5):2089-99. doi: 10.1128/AAC.00936-08. Epub 2009 Feb 17.

7.

Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.

Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S.

Expert Rev Vaccines. 2008 May;7(4):417-29. doi: 10.1586/14760584.7.4.417.

PMID:
18444889
8.

Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.

Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD.

Clin Vaccine Immunol. 2008 Mar;15(3):460-7. doi: 10.1128/CVI.00431-07. Epub 2008 Jan 23.

9.

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7.

PMID:
17940980
10.

Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents.

Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S421-9.

PMID:
17940979
11.

Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent.

Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, Bavari S, Aman MJ.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S276-83.

PMID:
17940961
12.

Involvement of vacuolar protein sorting pathway in Ebola virus release independent of TSG101 interaction.

Silvestri LS, Ruthel G, Kallstrom G, Warfield KL, Swenson DL, Nelle T, Iversen PL, Bavari S, Aman MJ.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S264-70.

PMID:
17940959
13.

NKp30-dependent cytolysis of filovirus-infected human dendritic cells.

Fuller CL, Ruthel G, Warfield KL, Swenson DL, Bosio CM, Aman MJ, Bavari S.

Cell Microbiol. 2007 Apr;9(4):962-76.

PMID:
17381429
14.

Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses.

Mohamadzadeh M, Coberley SS, Olinger GG, Kalina WV, Ruthel G, Fuller CL, Swenson DL, Pratt WD, Kuhns DB, Schmaljohn AL.

J Virol. 2006 Jul;80(14):7235-44.

15.

VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Mühlberger E.

Antimicrob Agents Chemother. 2006 Mar;50(3):984-93.

16.

Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.

Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S.

PLoS Pathog. 2006 Jan;2(1):e1. Epub 2006 Jan 13.

17.

Filovirus-like particles as vaccines and discovery tools.

Warfield KL, Swenson DL, Demmin G, Bavari S.

Expert Rev Vaccines. 2005 Jun;4(3):429-40. Review.

PMID:
16026254
18.

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S.

J Immunol. 2005 Jul 15;175(2):1184-91.

19.

Analysis of Ebola virus and VLP release using an immunocapture assay.

Kallstrom G, Warfield KL, Swenson DL, Mort S, Panchal RG, Ruthel G, Bavari S, Aman MJ.

J Virol Methods. 2005 Jul;127(1):1-9. Epub 2005 Apr 25.

PMID:
15893559
20.

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.

Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S.

Vaccine. 2005 Apr 27;23(23):3033-42.

PMID:
15811650
21.

Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation.

Pethe K, Swenson DL, Alonso S, Anderson J, Wang C, Russell DG.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13642-7. Epub 2004 Aug 31.

22.

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.

Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S.

Vaccine. 2004 Sep 3;22(25-26):3495-502.

PMID:
15308377
23.

Role of natural killer cells in innate protection against lethal ebola virus infection.

Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ, Yokoyama WM, Young HA, Bavari S.

J Exp Med. 2004 Jul 19;200(2):169-79. Epub 2004 Jul 12.

24.

Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein.

Swenson DL, Warfield KL, Kuehl K, Larsen T, Hevey MC, Schmaljohn A, Bavari S, Aman MJ.

FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):27-31.

25.

Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis.

Höner Zu Bentrup K, Miczak A, Swenson DL, Russell DG.

J Bacteriol. 1999 Dec;181(23):7161-7.

26.

Pneumonia in a long-term care facility. A prospective study of outcome.

Muder RR, Brennen C, Swenson DL, Wagener M.

Arch Intern Med. 1996 Nov 11;156(20):2365-70.

PMID:
8911243
27.

Two pathogenicity islands in uropathogenic Escherichia coli J96: cosmid cloning and sample sequencing.

Swenson DL, Bukanov NO, Berg DE, Welch RA.

Infect Immun. 1996 Sep;64(9):3736-43.

28.

Battling against host phagocytes: the wherefore of the RTX family of toxins?

Welch RA, Bauer ME, Kent AD, Leeds JA, Moayeri M, Regassa LB, Swenson DL.

Infect Agents Dis. 1995 Dec;4(4):254-72. Review.

PMID:
8665089
29.
30.
31.

The frequency of fim genes among Salmonella serovars.

Swenson DL, Clegg S, Old DC.

Microb Pathog. 1991 Jun;10(6):487-92.

PMID:
1686630
32.

Expression of type 1 fimbriae and mannose-sensitive hemagglutinin by recombinant plasmids.

Gerlach GF, Clegg S, Ness NJ, Swenson DL, Allen BL, Nichols WA.

Infect Immun. 1989 Mar;57(3):764-70.

Supplemental Content

Loading ...
Support Center